HHS draft policy does not intend to act against compounding six peptides that meet strict conditions

Aquesta entrada es mostra en anglès fins que se n'actualitzi la traducció.

The US Department of Health and Human Services announced a draft policy saying it does not intend to take enforcement action against state-licensed pharmacies, federal facilities or licensed physicians that compound BPC-157, epitalon, KPV, MOTS-c, semax or TB-500 while the FDA's 503A bulk substances list is developed through rulemaking, but only when every condition in the policy is met. Those conditions include using only the peptide form and route of administration the policy lists, one active ingredient per product, a patient-specific prescription, a raw ingredient made by an FDA-registered manufacturer following good manufacturing practice with a valid certificate of analysis (lab test report), and reporting serious adverse events to the FDA. The notice, published in the Federal Register on 30 October with written comments accepted for two weeks, says the policy is not binding and may be revisited if a safety signal or product quality issue arises. It does not approve these peptides or add them to the list, and compounded drugs are not reviewed by the FDA for safety, effectiveness or quality before they are marketed.

Fonts

  1. 01Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances(obre la font en una pestanya nova) Federal Register
  2. 02Draft Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances(obre la font en una pestanya nova) US Department of Health and Human Services
  3. 03HHS to allow compounders to make 6 unapproved peptides(obre la font en una pestanya nova) BioPharma Dive
  4. 04HHS Announces Draft Enforcement Discretion Policy Paving Way for Pharmacies to Compound Certain Peptides While FDA Rulemaking Is Pending(obre la font en una pestanya nova) Arnold & Porter

Pèptids implicats

  1. No aprovatBPC-157Pentadecapèptid gàstric sintètic (producte químic de recerca)15 Prohibit per la WADA
  2. No aprovatEpitalonTetrapèptid pineal sintètic (candidat a geroprotector)4 Prohibit per la WADA
  3. No aprovatKPVTripèptid derivat de l'alfa-MSH (producte químic de recerca)3 Prohibit per la WADA
  4. No aprovatMOTS-cPèptid d'origen mitocondrial (pèptid de recerca)16 Prohibit per la WADA
  5. Aprovat en altres païsosSemaxAnàleg del fragment ACTH(4-10) (neuropèptid derivat de la melanocortina)7
  6. No aprovatTB-500Fragment de la timosina beta-4 (producte químic de recerca)7 Prohibit per la WADA